Protection against cancer by dietary IP6 and inositol

Nutrition and Cancer

Volumn 55, Issue 2, 2006, Pages 109-125

  Vucenik, Ivana ^a   Shamsuddin, Abulkalam M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELL FORTE; CHOLESTEROL; DOXORUBICIN; INOCELL; INOSITOL; INOSITOL PHOSPHATE; NUTRACEUTICAL; PHYTIC ACID; TAMOXIFEN;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BLADDER PAPILLOMA; CANCER; CANCER INHIBITION; CANCER MODEL; CANCER PREVENTION; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CEREAL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DEPHOSPHORYLATION; DIETARY FIBER; DIETARY INTAKE; DISEASE MODEL; DRUG ABSORPTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG UPTAKE; GASTROINTESTINAL ABSORPTION; HUMAN; IMMUNITY; KIDNEY CALCIFICATION; LEGUME; LEUKOPENIA; MAMMAL CELL; METASTASIS; MINERAL DEFICIENCY; NAUSEA; NEPHROLITHIASIS; NONHUMAN; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; STOMACH ULCER; THROMBOCYTE DYSFUNCTION; THROMBOCYTOPENIA; TUMOR CELL DESTRUCTION; VOMITING; ZINC DEFICIENCY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; DIETARY FIBER; DISEASE MODELS, ANIMAL; HUMANS; INOSITOL; MICE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PHYTIC ACID; RATS; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 33750846875     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1207/s15327914nc5502_1     Document Type: Review

References (156)

1. Doll R and Peto R: The causes of cancer. J Natl Cancer Inst 66, 1191-1308, 1981.
2. Willet WC: Diet, nutrition and avoidable cancer. Environ Health Perspect 103(Supl 8), 165-170, 1995.
3. World Cancer Research Fund in association with the American Institute for Cancer Research: Food, Nutrition, and the Prevention of Cancer: A Global Perspective. Washington DC: American Institute for Cancer Research, 1997.
4. Slavin J: Why whole grains are protective: biological mechanism. Proc Nutr Soc 62, 129-134, 2003.
5. Burkitt DP: Epidemiology of cancer of the colon and rectum. Cancer 28, 3-13, 1971.
6. Doll R: The geographical distribution of colon cancer. Br J Cancer 23, 1-8, 1969.
7. Baghust PA and Rohan TE: High-fiber diets and reduced risk of breast cancer. Int J Cancer 56, 173-176, 1994.
8. Rose DP: Dietary fiber, phytoestrogens, and breast cancer. Nutrition 8, 47-51, 1992.
9. Peters U, Sinha R, Chatterjee N, Subar AF, Ziegler RG, et al.: Dietary fibre and colorectal adenoma in a colorectal cancer early detection programme. Lancet 361, 1491-1495, 2003.
10. Bingham SA, Day NE, Luben R, Ferrari P, Slimani N, et al.: Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet 361, 1496-1501, 2003.
11. Larson SC, Giovannucci E, Bergkvist L, and Wolk A: Whole grain consumption and risk of colorectal cancer: a population-based cohort of 60,000 women. Br J Cancer 92, 1803-1807, 2005.
12. Duncan AM: The role of nutrition in the prevention of breast cancer. AACN Clin Issues 15, 119-135, 2004.
13. Cohen LA: Dietary fiber and breast cancer. Anticancer Res 19, 3685-3688, 1999.
14. Ferguson LR and Harris PJ: Protection against cancer by wheat bran: role of dietary fibre and phytochemicals. Eur J Cancer Prev 8, 17-25, 1999.
15. Graf E and Eaton JW: Dietary suppression of colonic cancer: Fiber or phytate? Cancer 56, 717-718, 1985.
16. Harland BF and Oberleas D: Phytate in foods. World Rev Nutr Diet 52, 235-259, 1987.
17. Reddy NR, Sathe SK, and Salunke DK: Phytates in legumes and cereals. Adv Food Res 28, 1-89, 1982.
18. Berridge MJ and Irvine RF: Inositol phosphates and cell signalling. Nature 314, 197-205, 1989.
19. Sasakawa N, Sharif M, and Hanley MR: Metabolism and biological activities of inositol pentakisphosphates and inositol hexakisphosphate. Biochem Pharmacology 50, 137-146, 1995.
20. Shamsuddin AM: Cell signaling properties of inositol hexaphosphates. In: Nutrigenomics: The Role of Oxidants and Antioxidants in Gene Expression. Rimbach G and Packer L (eds). New York: Marcel Dekker, 2005, pp 397-420.
21. 6. Trends Biochem Sci 18, 53-65, 1993.
22. Nagata E, Luo HR, Saiardi A, Bae B, Suzuki N, et al.: Inositol hexakisphosphate kinase-2, a physiologic mediator of cell death. J Biol Chem 280, 1634-1640, 2005.
23. Seeds AM, Bastidas RJ, and York JD: Molecular definition of novel inositol polyphosphate metabolic pathway initiated by inositol 1,4,5-trisphosphate 3-kinase activity in Saccharomyces cerevisiae. J Biol Chem 280, 27654-27661, 2005.
24. Graf E and Eaton JW: Antioxidant functions of phytic acid. Free Radical Biol Med 8, 61-69, 1990.
25. Huisaman B and Lochner A: Inositol polyphosphates and their binding proteins-a short review. Mol Cell Biochem 157, 229-232, 1996.
26. Shears SB: Inositol pentakis- and hexakisphosphate metabolism adds versatility to the actions of inositol polyphosphates: novel effects on ion channels and protein traffic. Sub-Cellular Biochem 26, 187-226, 1996.
27. 2+ channel activity by inositol hexakisphosphate. Science 278, 471-474, 1997.
28. Zi X, Singh RP, and Agarwal R: Impairment of erbB1 receptor and fluid phase endocytosis and associated mitogenic signaling by inositol hexaphosphate in human prostate carcinoma DU145 cells. Carcinogenesis 21, 2225-2235, 2000.
29. 2+-mediated exocytosis of insulin by activation of protein kinase C. Proc Natl Acad Sci USA 94, 4435-4439, 1997.
30. Ji H, Sandberg K, Baukal AJ, and Catt KJ: Metabolism of inositol pentakisphosphate to inositol hexakisphosphate in Xenopus laevis oocytes. J Biol Chem 264, 20185-20188, 1989.
31. York JD, Odom AR, Murphy R, Ives EB, and Wente SR: A phospholipase C-dependent inositol polyphosphate kinase pathway required for efficient messenger RNA export. Science 285, 96-100, 1999.
32. Hanakahi LA, Bartlet-Jones M, Chappell C, Pappin D, and West SC: Binding of inositol phosphate to DNA-PK and stimulation of double-strand break repair. Cell 102, 721-729, 2000.
33. CS. J Biol Chem 277, 10756-10759, 2002.
34. Macbeth MR, Schubert HL, Vandemark AP, Lingam AT, Hill CP, et al.: Inositol hexakisphosphate is bound in the ADAR2 core and required for RNA editing. Science 309, 1534-1539, 2005.
35. 6 & inositol in cancer prevention and therapy. Current Cancer Therapy Rev 1, 259-269 2005.
36. 6) and inositol: from laboratory to clinic. J Nutr 133, 3778S-3784S, 2003.
37. Shamsuddin AM: Anti-cancer function of phytic acid. Int J Food Sci Technol 37, 769-782, 2002.
38. Fox CH and Eberl M: Phytic acid (IP6), a novel broad spectrum anti-neoplastic agent: a systemic review. Complement Ther Med 10, 229-234, 2002.
39. 6: a novel anti-cancer agent. Life Sci 61, 343-354, 1997.
40. Shamsuddin AM: Inositol phosphates have novel anticancer function. JNutr 12S, 725S-732S, 1995.
41. Shamsuddin AM, Elsayed A, and Ullah A: Suppression of large intestinal cancer in F344 rats by inositol hexaphosphate. Carcinogenesis 9, 577-580, 1988.
42. Shamsuddin AM, Ullah A, and Chakravarthy A: Inositol and inositol hexaphosphate suppress cell proliferation and tumor formation in CD-I mice. Carcinogenesis 10, 1461-1463, 1989.
43. Shamsuddin AM and Ullah A: Inositol hexaphosphate inhibits large intestinal cancer in F344 rats 5 months after induction by azoxymethane. Carcinogenesis 10, 625-626, 1989.
44. Ullah A and Shamsuddin AM: Dose-dependent inhibition of large intestinal cancer by inositol hexaphosphate in F344 rats. Carcinogenesis 11, 2219-2222, 1990.
45. Nelson RL, Yoo SJ, Tanure JC, Andrianopoulos G, and Misumi A: The effect of iron on experimental colorectal carcinogenesis. Anticancer Res 9, 1477-1482, 1989.
46. Shivapurkar N, Tang ZC, Frost A, and Alabaster O: A rapid dual organ rat carcinogenesis bioassay for evaluating the chemoprevention of breast and colon cancer. Cancer Lett 100, 169-179, 1996.
47. Pretlow TP, O'Riordan MA, Somich GA, Amini SB, and Pretlow TG: Aberrant crypts correlate with tumor incidence in F344 rats treated with azoxymethane and phytate. Carcinogenesis 13, 1509-1512, 1992.
48. Challa A, Rao DR, and Reddy BS: Interactive suppression of aberrant crypt foci induced by azoxymethane in rat colon by phytic acid and green tea. Carcinogenesis 18, 2023-2026, 1997.
49. Jenab M and Thompson LU: Phytic acid in wheat bran affects cell morphology, differentiation and apoptosis. Carcinogenesis 21, 1547-1552, 2000.
50. Thompson LU and Zhang L: Phytic acid and minerals: effect of early markers of risk for mammary and colon carcinogenesis. Carcinogenesis 12, 2041-2045, 1991.
51. Vucenik I, Sakamoto K, Bansal M, and Shamsuddin AM: Inhibition of mammary carcinogenesis by inositol hexaphosphate (phytic acid): a pilot study. Cancer Lett 75, 95-102, 1993.
52. Vucenik I, Yang G-Y, and Shamsuddin AM: Inositol hexaphosphate and inositol inhibit DMBA induced rat mammary cancer. Carcinogenesis 16, 1055-1058, 1995.
53. 6) and high-bran diet in the prevention of DMBA-induced rat mammary carcinogenesis. Nutr Cancer 28, 7-13, 1997.
54. Hirose M, Hoshiya T, Akagi K, Futakushi M, and Ito N: Inhibition of mammary gland carcinogenesis by green tea catechin and other naturally occurring antioxidants in Sprague-Dawley rats pretreated with 7,12-dimethylbenz[a] anthracene. Cancer Lett 83, 149-156, 1994.
55. 6 in vivo: initiation-promotion model. Anticancer Res 19, 3749-3752, 1999.
56. Gupta KP, Singh J, and Bharathi R: Suppression of DMBA-induced mouse skin tumor development by inositol hexaphosphate and its mode of action. Nutr Cancer 46, 66-72, 2003.
57. Lee HJ, Lee SA, and Choi H: Dietary administration of inositol and/or inositol-6-phosphate prevents chemically-induced rat hepatocarcinogenesis. Asian Pac J Cancer Prev 6, 41-47, 2005.
58. Vucenik I, Tomazic VJ, Fabian D, and Shamsuddin AM: Antitumor activity of phytic acid (inositol hexaphosphate) in murine transplanted and metastatic fibrosarcoma, a pilot study. Cancer Lett 65, 9-13, 1992.
59. Jariwalla RJ, Sabin R, Lawson S, Bloch DA, Prender M, et al.: Effects of dietary phytic acid (phytate) on the incidence and growth rate of tumors promoted in Fisher rats by a magnesium supplement. Nutrition Res 8, 813-827, 1988.
60. 6): inhibition oh human rhabdomyosarcoma in vitro and in vivo. Anticancer Res 18, 1377-1384, 1998.
61. Hirose M, Ozaki K, Takaba K, Fukushima S, Shirai T, et al.: Modifying effects of the naturally occurring antioxidants g-oryzanol, phytic acid, tannic acid and n-tritriacontane-16,18-dione in rat a wide-spectrum organ carcinogenesis model. Carcinogenesis 12, 1917-1921, 1991.
62. 6 regresses pre-existing human liver cancer xenotransplanted in nude mice. Anticancer Res 18, 4091-4096, 1998.
63. Singh PR, Sharma G, Mallikarjuna GU, Dhanalakshmi S, Aragwal C, et al.: In vivo suppression of hormone-refractory prostate cancer growth by inositol hexaphosphate: induction of insulin-like growth factor binding protein-3 and inhibition of vascular endothelial growth factor. Clin Cancer Res 10, 244-250, 2004.
64. Estensen RD and Wattenberg LW: Studies of chemopreventive effects of myo-inositol on benzo[a]pyrene-induced neoplasia of the lung and forestomach of female A/J mice. Carcinogenesis 14, 1975-1977, 1993.
65. Wattenberg LW: Chalcones, myo-inositol and other novel inhibitors of pulmonary carcinogenesis. J Cell Biochem 22 (Suppl), 162-168, 1995.
66. 3H]-Phytic acid (inositol hexaphosphate) is absorbed and distributed to various tissues in rats. J Nutr 123, 713-720, 1993.
67. 3H]-Inositol hexaphosphate (phytic acid) is rapidly absorbed and metabolized by murine and human malignant cells in vitro. J Nutr 124, 861-868, 1994.
68. Ferry S, Matsuda M, Yoshida H, and Hirata M: Inositol hexakisphosphate blocks tumor cell growth by activating apoptotic machinery as well as by inhibiting the Akt/NFkB-mediated cell survival pathway. Carcinogenesis 23, 2031-2041, 2002.
69. 3) in malignant cells, tissues and biological fluids. Life Sci 71, 1535-1546, 2002.
70. Shamsuddin AM, Baten A, and Lalwani ND: Effect of inositol hexaphosphate on growth and differentiation in K562 erythroleukemia cell line. Cancer Lett 64, 195-202, 1992.
71. 6 or phytate) in humans. BioFactors 15, 53-61, 2001.
72. 6) on human normal and leukaemic hematopoietic cells. Brit J Haematology 117, 577-587, 2002.
73. Sakamoto K, Venkatraman G, and Shamsuddin AM: Growth inhibition and differentiation of HT-29 cells in vitro by inositol hexaphosphate (phytic acid). Carcinogenesis 14, 1815-1819, 1993.
74. 6: growth inhibition and differentiation of human mammary cancer cell lines in vitro. Anticancer Res 16, 3287-3292, 1996.
75. Dorsey M, Benhuzzi H, Tucci M, and Cason Z: Growth and cell viability of estradiol and IP-6 treated Hep-2 laryngeal carcinoma cells. Blamed Sci Instrum 41, 205-210, 2005.
76. Shamsuddin AM and Yang G-Y: Inositol hexaphosphate inhibits growth and induces differentiation of PC-3 human prostate cancer cells. Carcinogenesis 16, 1975-1979, 1995.
77. 1 arrest and apoptotic death of prostate carcinoma DU145: modulation of CDKI-CDK-cyclin and pRb-related protein-E2F complexes. Carcinogenesis 24, 555-563, 2003.
78. Agarwal C, Dhanalakshmi S, Singh RP, and Agarwal R: Inositol hexaphosphate inhibits growth and induces G1 arrest and apoptotic death of androgen-dependent human prostate carcinoma LNCaP cells. Neoplasia 6, 646-659, 2004.
79. 6 inhibits growth and reverses transformed phenotype in HepG2 human liver cancer cell line. Anticancer Res 18, 4083-4090, 1998.
80. 6): a novel treatment for pancreatic cancer. J Surg Res 126, 199-203, 2005.
81. 6) inhibits cellular proliferation in melanoma. J Surg Res 133, 3-6, 2006.
82. 6-induced growth inhibition and differentiation of HT-29 human colon cancer cells: involvement of intracellular inositol phosphates. Anticancer Res 15, 2479-2488, 1995.
83. 6): an antagonist of fibroblast growth factor receptor binding and activity. In vitro Cell Dev Biol 30A, 783-789, 1994.
84. Huang C, Ma W-Y, Hecht SS, and Dong Z: Inositol hexaphosphate inhibits cell transformation and activator protein 1 activation by targeting phosphatidylinositol-3′ kinase. Cancer Res 57, 2873-2878, 1997.
85. Nickel KP and Belury MA: Inositol hexaphosphate reduces 12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase independent of protein kinase C isoform expression in keratinocytes. Cancer Lett 140, 105-111, 1999.
86. 6) differentially modulates the expression of PKCδ in MCF-7 and MDA-MB 231 cells. Proc Amer Assoc Cancer Res 40, 653, 1999.
87. Vucenik I and Ramljak D: The contradictory role of PKC5 in cellular signaling. Breast Cancer Res Treat 97, 1-2, 2005.
88. Solyakov L, Cain K, Tracey BM, Jukes R, Riley AM, et al.: Regulation of casein kinase-2 (CK-2) activity by inositol phosphates. J Biol Chem 279 ,43403-43410, 2004.
89. Muraoka S and Miura T: Inhibition of xanthine oxidase by phytic acid and its antioxidative action. Life Sci 74, 1691-1700, 2004.
90. Rao PS, Liu XK, Das DK, Weinstein GS, and Tyras DH: Protection of ischemic heart from reperfusion injury by myo-inositol hexaphosphate, a natural antioxidant. Ann Thorac Surgery 52, 908-912, 1991.
91. Kamp DW, Israbian VA, Yeldandi AV, Panos RJ, Graceffa P, et al.: Phytic acid, an iron chelator, attenuates pulmonary inflammation and fibrosis in rats after intratracheal instillation of asbestos. Toxicol Pathol 23, 689-695, 1995.
92. Sudher Kumar M, Sridhar Reddy B, Kiran Babu S, Bhilegaonkar PM, Shirwaikar A, et al.: Antiinflammatory and antiulcer activities of phytic acid in rats. Indian J Exp Biol 42, 179-185, 2004.
93. Singh A, Singh SP, and Bamezai R: Modulatory influence of arecoline on the phytic acid-altered hepatic biotransformation system enzymes, sulfhydryl content and lipid peroxidation in a murine system. Cancer Lett 117, 1-6, 1997.
94. Porres JM, Stahl CH, Cheng WH, Fu Y, Roneker KR, et al.: Dietary intrinsic phytate protects colon from lipid peroxidation in pigs with a moderately high dietary iron intake. Proc Soc Exp Biol Med 221, 80-86, 1999.
95. Nascimento NR, Lessa LM, Kerntopf MR, Sousa CM, Alves RS, et al.: Inositols prevents and reverse endothelial dysfunction in diabetic rat and rabbit vasculature metabolically and by scavenging superoxide. Proc Natl Acad Sci USA 103, 218-223, 2006.
96. Baten A, Ullah A, Tomazic VJ, and Shamsuddin AM: Inositol-phosphate- induced enhancement of natural killer cell activity correlates with tumor suppression. Carcinogenesis 10, 1595-1598, 1989.
97. Zhang Z, Song Y, and Wang X-L: Inositol hexaphosphate-induced enhancement of natural killer cell activity correlates with suppression of colon carcinogenesis in rats. World J Gastroenterol 11, 5044-5046, 2005.
98. 6 on human neutrophil cytokine production and cell morphology. Anticancer Res 19, 371 1-3716, 1999.
99. Kip1 and decrease in retinoblastoma protein (pRb) phosphorylation. Breast Cancer Res Treat 91, 35-45, 2005.
100. 6). Anticancer Res 21, 2393-2404, 2001.
101. 6) on AIDS neoplastic Kaposi's sarcoma, iatrogenic Kaposi's sarcoma and lymphoma. Proc Amer Assoc Cancer Res 40, 499, 2003.
102. Xu Q, Kanthasamy G, and Reddy MB: Phytic acid protects against 6-OHDA and iron induced apoptosis in cell culture model of Parkinson's disease. FASEB J 20, A192, 2006.
103. Jagadeesh S and Banerjee PP: Inositol hexaphosphate represses telomerase activity and translocate TERT from the nucleus in mouse and human prostate cancer cells via the deactivation of Akt and PKCalpha. Biochem Biophys Res Commun Sept 15 [Epub ahead of print]. 2006.
104. 6). Carcinogenesis 25, 2115-2123, 2004.
105. 6) inhibits key events of cancer metastases, I: in vitro studies of adhesion, migration and invasion of MDA-MB 231 human breast cancer cells. Anticancer Res 23, 3671-3679, 2003.
106. 6) inhibits key events of cancer metastases, II: effects on integrins and focal adhesions. Anticancer Res 23, 3681-3689, 2003.
107. Green ES, Zangerl AR, and Berenbaum MR: Effects of phytic acid and xanthotoxin on growth and detoxification in caterpillars. J Chem Ecol 27, 1763-1773, 2001.
108. Katayama T: Effect of dietary sodium phytate on the hepatic and serum levels of lipids and on the hepatic activities of NADH-generating enzymes in rats fed on sucrose. Biosci Biotech Biochem 59, 1159-1160, 1995.
109. Katayama T: Effects of dietary myo-inositol or phytic acid on hepatic concentrations of lipids and hepatic activities of lipogenic enzymes in rats fed on corn starch or sucrose. Nutrition Res 4, 721-728, 1997.
110. Arnold JT, Wilkinson BP, Sharma S, and Steele VE: Evaluation of chemopreventative agents in different mechanistic classes using a rat epithelial cell culture transformation assay. Cancer Res 73, 537-543, 1993.
111. Babich H, Borenfreund E, and Stern A: Comparative toxicities of selected minor dietary non-nutrients with chemopreventive properties. Cancer Lett 73, 127-133, 1993.
112. 6) enhances the anti-proliferative effects of adriamycin and tamoxifen in breast cancer. Breast Cancer Res Treat 79, 301-312, 2003.
113. Onomi S, Okazaki Y, and Katayama T: Effect of dietary level of phytic acid on hepatic and serum lipid status in rats fed a high-sucrose diet. Biosci Biotechnol Biochem 68, 1379-1381, 2004.
114. Jariwalla RJ, Sabin R, Lawson S, and Herman ZS: Lowering of serum cholesterol and triglycerides and modulations by dietary phytate. J Appl Nutr 42, 18-28, 1990.
115. 6). Anticancer Res 19, 3689-3693, 1999.
116. 6) reduces risk for cancer and cardiovascular diseases. Period Biol 99, 25-30, 1997.
117. Shimazawa M, Watanabe S, Kondo K, Hara H, Nakashima M, et al.: Neutrophil accumulation promotes intimal hyperplasia after photochemically induced arterial injury in mice. Europ J Pharmacol 520, 156-163, 2005.
118. Grases F, Sanchis P, Perello J, Isern B, Prieto RM, et al.: Phytate (Myo-inositol hexakisphosphate) inhibits cardiovascular calcifications in rats. Front Biosci 11, 136-42, 2006.
119. Barker CJ and Berggren PO: Inositol hexakisphosphate and b-cell stimulus-secretion coupling. Anticancer Res 19, 3737-3742, 1999.
120. Lehtihet M, Honkanen RE, and Sjöholm Å: Inositol hexakisposphate and sulfonylureas regulate b-cell protein phosphatases. Biochem Biophys Res Commun 316, 893-897, 2004.
121. Dilworth LL, Omoruyi FO, Simon OR, Morrison EY, and Asemota HN: The effect of phytic acid on the levels of blood glucose and some enzymes of carbohydrate and lipid metabolism. West Indian Med J 54, 102-106, 2005.
122. Friend M, Vucenik I, and Miller M: Platelet responsiveness to aspirin in patients with hyperlipidemia. Brit Med J 326, 82-83, 2003.
123. Henneman PH, Benedict PH, Forbes AP, and Dudley HR: Idiopathic hypercalciuria. N Engl J Med 17, 802-807, 1958.
124. Grases F, Garcia-Gonsales R, Torres JJ, and Llobera A: Effects of phytic acid on renal stone formation in rats. Scand J Urol Nephrol 32, 261-265, 1988.
125. Ohkawa T, Ebisuno S, Kitagawa M, Marimoto S, Miyazaki Y, et al.: Rice bran treatment for patients with hypercalciuric stones: experimental and clinical studies. J Urol 132, 1140-1145, 1984.
126. Grases F, March JG, Prieto RM, Simonet BM, Costa-Bauzá A, et al.: Urinary phytate in calcium oxalate stone-formers and healthy people: dietary effects on phytate excretion. Scand J Urol Nephrol 34, 162-164, 2000.
127. Curhan GC, Willett WC, Knight EL, and Stampfer MJ: Dietary factors and the risk of incident kidney stones in younger women: Nurses' Health Study 11. Arch Intern Med 164, 885-891, 2004.
128. Grases F, Perelló J, Prieto RM, Simonet BM, and Torres JJ: Dietary myo-inositol prevents dystrophic calcifications in soft tissues: a pilot study in Wistar rats. Life Sci 75, 11-19, 2004.
129. 6 + Inositol as adjuvant to chemotherapy of colon cancer: our clinical experience. Anticancer Res 24, 3474, 2004.
130. Druzijanic N, Juricic J, Perko Z, and Kraljevic D: IP-6 & Inositol: adjuvant to chemotherapy of colon cancer. A pilot clinical trial. Rev Oncologia 4(Suppl 1 ), 171, 2002.
131. 6 + Inositol in treatment of ductal invasive breast carcinoma: our clinical experience. Anticancer Res 24, 3475, 2004.
132. 6 plus Inositol treatment after surgery and post-operative radiotherapy: report of a case: breast cancer. Anticancer Res 24, 3617, 2004.
133. 6) plus Inositol treatment combined with chemo-radiotherapy: report of a case. Anticancer Res 24, 3618, 2004.
134. Sausville E: Personal communication, National Cancer Institute, Bethesda, Maryland USA, July 1, 1999.
135. Walker ARP, Fox FW, and Irving JT: Studies in human mineral metabolism, I: the effect of bread rich in phytate phosphorous on the metabolism of certain mineral salts with special reference to calcium. Biochem J 42, 452-462, 1948.
136. Cullumbine H, Basnayake V, and Lemottee J: Mineral metabolism on rice diets. Brit J Nutr 4, 101-111, 1950.
137. Kelsay JL: Effect of fiber, phytic acid, and oxalic acid in the diet on mineral bioavailability. Am J Gastroent 278, 983-986, 1987.
138. Sandstrom B, Bugel S, McGaw BA, Price J, and Reid MD: A high oat-bran intakes does not impair zinc absorption in human when added to a low-fiber animal protein-based diet. J Nutr 130, 594-599, 2000.
139. Manary MJ, Hotz C, Krebs NF, Gibson RS, Westcott JE, et al.: Dietary phytate reduction improves absorption in Malawian children recovering from tuberculosis but not in well children. J Nutr 130, 2959-2964, 2000.
140. Siqueira EM, Arruda SF, de Sousa LM, and de Sousa EM: Phytate from an alternative dietary supplement has no effect on the calcium, iron and zinc status in undernourished rats. Arch Latinoam Nutr 51, 250-257, 2001.
141. Grases F, Simonet BM, Perelló J, Costa-Bauzá A, and Prieto RM: Effect of phytate on element bioavalability in the second generation of rats. J Trace Elem Med Biol 17, 229-234, 2004.
142. Ma G, Jin Y, Piao J, Kok F, Guusje B, et al.: Phytate, calcium, iron, and zinc contents and molar ratios in foods commonly consumed in China. J Agric Food Chem 53, 10285-10290, 2005.
143. Szkudelski T: Phytic acid-induced metabolic changes in rat. J Anim Physiol Anim Nutr (Bed) 89, 397-402, 2005.
144. Yangklang C, Wensing T, Lemmens AG, Jittakhot S, and Beynen AC: Effect of sodium phytate supplementation on fat digestion and cholesterol metabolism in female rat. J Anim Physiol Anim Nutr (Berl) 89, 373-378, 2005.
145. Harland B: Rat plasma cooper and zinc concentrations were not nega-tively affected by high phytate of "Black Seed." FASEB J 20, A196, 2006.
146. Kristensen MB, Hels O, Morberg CM, Marving J, Bügel S, et al.: Total zinc absorption in young women, but not fractional zinc absorption, differs between vegetarian and meat-based diets with equal phytic acid content. Br J Nutr 95, 963-967, 2006.
147. Takaba K, Hirose M, Ogawa K., Hakoi K, and Fukushima S: Modification of N-butyl-N-(4-hydroxylbutl)nitrosamine-initiated urinary bladder carcinogenesis in rats by phytic acid and salts. Food Chem Toxicol 32, 499-503, 1994.
148. Hiasa Y, Kitahori Y, Morimoto J, Konishi N, Nakaoka S, et al.: Carcinogenicity study in rats of phytic acid "Daiichi," a natural food additive. Food Chem Toxic 30, 117-125, 1992.
149. 6), from rats to humans. Anticancer Res 25, 2593-2597, 2005.
150. Iqbal TH, Lewis KO, and Cooper BT: Phytase activity in the human and rat small intestine. Gut 35, 1233-1236, 1994.
151. 6) through skin. Biol Pharm Bull 28, 764-767, 2005.
152. Coppolino CA: Hexa-citrated phytate and process of preparation thereof. US Patent No 7,009,067.
153. Coppolino CA and Shamsuddin AM: Novel phytic citrate compounds and process for preparing the same. US Patent Application # 11/320,834, December 30, 2005.
154. Abelson PH: A potential phosphate crisis. Science 283, 2015-2016, 1999.
155. Rafacz-Livingston KA, Martinez-Amezcua C, Parsons CM, Baker DH, and Snow J: Citric acid improves phytate phosphorus utilization in crossbred and commercial broiler chicks. Poult Sci 84, 1370-1375, 1999.
156. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al.: Cancer Statistics, 2006. CA Cancer J Clin 56, 106-130, 2006.